People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

846-P - Safety, Pharmacokinetics, and Pharmacodynamics of MBX 1416, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers: A Phase 1 Randomized Trial Presenter: Elisa Fabbrini, MD. PhD.

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they ...

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and ...

TUCSON, AZ / ACCESS Newswire / June 2, 2025 / Umbrella Labs , a leading supplier of advanced research chemicals, announced the expansion of its peptide catalog to include Retatrutide (LY3437943 ...

846-P - Safety, Pharmacokinetics, and Pharmacodynamics of MBX 1416, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers: A Phase 1 Randomized Trial Presenter: Elisa Fabbrini, MD. PhD.

The hormone glucagon-like peptide 1 (GLP-1) ... and approach the 30% weight reduction seen with bariatric surgery, potentially offering more consistent and lasting results. ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...